Improvement of disability and akinesia of patients with Parkinson's disease by intravenous iron substitution.
Akinetic crises are one of the problems arising in patients with Parkinson's disease in particular after long term treatment with levo-dihydroxyphenylalanine (L-DOPA). They are characterized by severe disability to move. Increasing dosages of L-DOPA and decarboxylase or monoaminooxidase inhibitors do not improve these symptoms. Intravenously applied iron in the form of a ferri-ferro-complex exhibits a considerable benefit for all patients treated so far. They regained a remarkable mobility. Their disability score dropped from up to 90 percent down to 30 percent. The effect is dosage-dependent, and withdrawal of iron will lead again to akinetic crises.
D015083:2,3-Diketogulonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D000496:Alloxan / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009068:Movement; D010300:Parkinson Disease / Q000503:physiopathology* / Q000628:therapy; D013400:Sugar Acids / Q000627:therapeutic use*
D004338:Drug Combinations; D005290:Ferric Compounds; D013400:Sugar Acids; D015083:2,3-Diketogulonic Acid; C008747:oxyferriscorbone; D000496:Alloxan